![Sebastian Inger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jeppe Ragnar Andersen | M | - |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Daniel José López-Cruz | M | 59 |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Celine Infeld | F | - |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Dänemark | 3 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sebastian Inger
- Persönliches Netzwerk